Business
Wearable technology demonstrates high compliance
Wearable technology demonstrates high compliance.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 5807X Cambridge Cognition Holdings PLC 28 November 2017 \n\nCambridge Cognition Holdings Plc\n('Cambridge Cognition' or the 'Company')\nWearable technology demonstrates high compliance\n \nThe digital neuroscience company Cambridge Cognition Holdings plc, (AIM: COG, 'the Company'), which develops and markets software products to improve brain health, has released positive results from a pilot study to evaluate cognition and mood using wearable technology in patients with major depressive disorder (MDD) at the 2017 International CNS Summit in Boca Raton, FL.\nThe study was sponsored by Takeda Pharmaceuticals and used Cognition Kit™ technology, developed in a joint venture between Cambridge Cognition and Ctrl Group to measure mood and cognition in real world settings.\nCollecting data in normal, day-to-day circumstances is a growing trend in the healthcare industry. Pharmaceutical companies now aim to demonstrate evidence of successful real world outcomes to differentiate their products in a competitive market while also satisfying the demands of payers and patients.\nReal world evidence can help improve health outcomes for patients, reduce medical costs and demonstrate the cost-effectiveness of a treatment. However, conducting studies outside of a clinical setting and gaining compliance from patients when unsupervised has to date been challenging.\nIn the reported study, thirty participants aged 18-65 with a clinical diagnosis of mild to moderate depression who had been prescribed antidepressants took part over a 6-week period, being assessed daily at regular intervals on the Apple Watch®.\nThe researchers found that patients were highly compliant with the wearable Cognition Kit technology on a daily basis to evaluate their mood (95 percent compliant) and cognitive health (96 percent compliant).\nThe data collected with Cognition Kit shows how wearable technology can be used to collect real world evidence reliably even in challenging patient groups and how it may also aid communication between patients and clinicians, ensuring symptoms are detected early.\nDr. Francesca Cormack, Director of Research and Innovation, at Cambridge Cognition said: \"We are delighted by the study results. These findings demonstrate that high frequency, near-patient testing using Cognition Kit software on wearable devices i...